DEP HER2-ADC / Starpharma - LARVOL DELTA

Starpharma Receives $5.5M R&D Tax Incentive Refund (Starpharma Press Release) - "Starpharma...today announces that it has received a $5.5M Research and Development (R&D) Tax Incentive refund for the 2024 financial year. The refund is associated with eligible R&D activities across Starpharma’s portfolio, including the company’s DEP drug delivery programs and VIRALEZE....The Australian Government's R&D Tax Incentive program provides a refundable tax offset to companies such as Starpharma that are undertaking eligible R&D activities. This initiative aims to encourage investment in R&D, fuelling innovation and ultimately boosting Australia's global competitiveness, driving economic growth and creating job opportunities."

Financing • Breast Cancer • Castration-Resistant Prostate Cancer • Gastroesophageal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Infectious Disease • Metastatic Castration-Resistant Prostate Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor